Clinical Trials

Four phase I/II clinical trials to evaluate the safety and efficacy of LOAd703 are currently ongoing.  

 

LOKON001

In this study (NCT02705196), patients suffering from pancreatic cancer are enrolled. The study is divided in two enrollment arms. In arm 1, patients are treated with up to 12 injections of LOAd703 every two weeks while receiving standard-of-care gemcitabine and nab-paclitaxel chemotherapy (day 1, 8 and 15 of a 28 day cycle). This arm is now completed and data will be published soon. In arm 2, patients are treated with up to 12 injections of LOAd703 plus the gemcitabine and nab-paclitaxel chemotherapy. In addition, the checkpoint antibody atezolizumab (anti-PDL1) is administered every fourth week. We are still enrolling patients in arm 2. Read more about the study and find contact information at www.clinicaltrials.gov. Search for "LOKON001". The study site is in Houston, TX.

 

LOKON002

In this study (NCT03225989), patients suffering from pancreatic cancer, ovarian cancer, colorectal cancer and biliary cancer are enrolled. Patients are treated with up to 8 injections of LOAd703 every two weeks while receiving standard-of-care chemotherapy tailored to the indication. Read more about the study and find contact information at www.clinicaltrials.gov. Search for "LOKON002". The study sites are in Uppsala and Stockholm, Sweden.

 

LOKON003

In this study (NCT04123470), patients suffering from malignant melanoma refractory to checkpoint blockade antibody therapy are enrolled. Patients are treated with LOAd703 in combination with the checkpoint inhibitor atezolizumab (anti-PDL1). Both are administered every third week. Read more about the study and find contact information at www.clinicaltrials.gov. Search for "LOKON003". The study sites are in Uppsala (Sweden), Houston (TX), and Los Angeles (CA).

 

MORPHEUS-CRC

This is a study Sponsored by Hoffmann La Roche. In this study (NCT03555149), patients suffering from colorectal cancer are enrolled. Atezolizumab (anti-PDL1) and LOAd703 will be administered every third week. Read more about the study and find contact information at www.clinicaltrials.gov. Search for "MORPHEUS-CRC". This is a multinational study.

How To Do if You Want to Participate in a Trial

If you are interested to participate as a study patient in our trials, please discuss with your treating physician. The treating physician can read the study details at www.clinicaltrials.gov to find out if Your cancer type and health status matches the so called inclusion and exclusion criteria. Your treating physician can then contact the study site to get information if it is possible to enroll You, or to put You on a waiting list. There is unfortunately not always a slot available to enroll patients. 

Developing cutting-edge 

cancer immunotherapy